Sabrina Martucci Johnson serves as President, Chief Executive Officer, Secretary, Director of the company. Ms. Johnson founded Daré Operations and has served as its President, Chief Executive Officer, Secretary and a member of the Board of Directors since its inception. Ms. Johnson is a life sciences executive committed to advancing improvements in women’s healthcare. Prior to founding Daré Operations, Ms. Johnson was President of WomanCare Global Trading, a specialty pharmaceutical company in female reproductive healthcare with commercial product distribution in over 100 countries, from October of 2014 to May of 2015. Before serving as President of WomanCare Global Trading, Ms. Johnson provided financial consulting services to the WomanCare Global family of companies, including the for-profit Trading division as well as the United Kingdom-based non-profit division, from November of 2012 to July of 2013, when she joined full time as WomanCare’s Chief Financial Officer and Chief Operating Officer until becoming President of the Trading division. In addition, Ms. Johnson served as Chief Operating Officer and Chief Financial Officer of Cypress Bioscience, Inc. until its sale in 2010. Ms. Johnson also held marketing and sales positions with Advanced Tissue Sciences and Clonetics Corporation. She began her career in the biotechnology industry as a research scientist with Baxter Healthcare, Hyland Division, working on their recombinant factor VIII program.
Sabrina Johnson is 54, she's been the President, Chief Executive Officer, Secretary oraz Director of Dare Bioscience Inc since 2017. There are 7 older and 4 younger executives at Dare Bioscience Inc. The oldest executive at Dare Bioscience Inc is William Rastetter, 72, who is the Independent Chairman of the Board.
Sabrina's mailing address filed with the SEC is 3655 NOBEL DRIVE, SUITE 260, SAN DIEGO, CA, 92122.
Over the last 7 years, insiders at Dare Bioscience Inc have traded over $0 worth of Dare Bioscience Inc stock and bought 594,545 units worth $703,000 . The most active insiders traders include William H Rastetter, Roger Hawley oraz Cheryl R Blanchard. On average, Dare Bioscience Inc executives and independent directors trade stock every 152 days with the average trade being worth of $969,110. The most recent stock trade was executed by Roger Hawley on 11 April 2019, trading 454,545 units of DARE stock currently worth $500,000.
daré bioscience (nasdaq: dare) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. we are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. we are initially focused on the areas of contraception, vaginal health and fertility. our lead product candidate, ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies.
Dare Bioscience Inc executives and other stock owners filed with the SEC include: